StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Prelude Therapeutics (PRLD)

Wed, 15 Jul 2026 07:39:13 -0400

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $8.00 price target on Prelude Therapeutics (NASDAQ: PRLD).

The analyst commented: ' Earlier this month, CSPC Pharmaceutical (HKG: 1093; not rated) announced that it has initiated a Phase 1 trial in China (NCT07692776) evaluating SYH-2095 (a KAT6A/B inhibitor) for the treatment of advanced malignant tumors as a monotherapy or in combination regimens. With SYH-2095 entering clinical testing, the number of KAT6 inhibitors currently in development has increased to 12. Although competition within the KAT6 inhibitor landscape is growing, we highlight the encouraging preclinical data that Prelude presented at AACR 2026 for

Form SCHEDULE 13G Prelude Therapeutics Filed by: Soleus Private Equity Fund III, L.P.

Wed, 08 Jul 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260708/26748383.html

Form SCHEDULE 13G Prelude Therapeutics Filed by: Soleus Private Equity Fund III, L.P.

Wed, 08 Jul 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260708/26748383.html

Prelude Therapeutics (PRLD) Reiterated at Market Outperform by Citizens

Wed, 01 Jul 2026 04:53:20 -0400

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $6.00 price target on Prelude Therapeutics (NASDAQ: PRLD).

The analyst commented, "File IND for KAT6A degrader PRT13722 and initiate Phase 1 study. Prelude’s second clinical program since its strategic reset is PRT13722, a highly selective KAT6A degrader for ER+/HER2− breast cancer. AACR 2026 preclinical data showed picomolar KAT6A degradation with high selectivity over KAT6B and other MYST proteins, deeper and more complete tumor regressions than Pfizer’s KAT6A/B inhibitor prifetrastat in head-to-head ER+/HER2− CDX and PDX models, and 100% (8/8) durable complete responses in a posttamoxifen PDX model. As importantly, PRT13722 showed

Form 4 Prelude Therapeutics For: Jun 09 Filed by: 667, L.P.

Wed, 10 Jun 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260610/26630550.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: 667, L.P.

Wed, 10 Jun 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260610/26630550.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: Babler Martin

Wed, 10 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260610/26630077.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: Babler Martin

Wed, 10 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260610/26630077.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: Dorton Katina

Wed, 10 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260610/26630103.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: Dorton Katina

Wed, 10 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260610/26630103.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: Bonita David P

Wed, 10 Jun 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260610/26630037.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: Bonita David P

Wed, 10 Jun 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260610/26630037.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: Sandor Victor

Wed, 10 Jun 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260610/26630019.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: Sandor Victor

Wed, 10 Jun 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260610/26630019.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: FRIEDMAN PAUL A

Wed, 10 Jun 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260610/26630013.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: FRIEDMAN PAUL A

Wed, 10 Jun 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260610/26630013.html

Form 8-K Prelude Therapeutics For: Jun 09

Wed, 10 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260610/26629990.html

Form 8-K Prelude Therapeutics For: Jun 09

Wed, 10 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260610/26629990.html

Goldman Sachs Starts Prelude Therapeutics (PRLD) at Early-Stage Biotech

Fri, 15 May 2026 05:07:25 -0400

Goldman Sachs analyst Corinne Johnson initiates coverage on Prelude Therapeutics (NASDAQ: PRLD) with a Early-Stage Biotech rating.

The analyst comments "We initiate coverage of Prelude Therapeutics (PRLD) at Early-Stage Biotech. PRLD is a clinical-stage biotech company with a pipeline of candidates focused on innovative medicines for cancers with high unmet needs; its lead programs include highly selective KAT6A degrader (PRT-13722) for metastatic breast cancer (mBC) and mutant-selective JAK2 inhibitor (PRT-12396) for Myeloproliferative Neoplasms (MPNs). We view the key debate for PRLD over the next several years will be whether its KAT6A degrader asset, PRT-13722, will be meaningfully differentiated in a crowded

Goldman Sachs Starts Prelude Therapeutics (PRLD) at Early-Stage Biotech

Fri, 15 May 2026 05:07:25 -0400

Goldman Sachs analyst Corinne Johnson initiates coverage on Prelude Therapeutics (NASDAQ: PRLD) with a Early-Stage Biotech rating.

Goldman Sachs Starts Prelude Therapeutics (PRLD) at Early-Stage Biotech

Fri, 15 May 2026 05:07:25 -0400

Goldman Sachs analyst Corinne Johnson initiates coverage on Prelude Therapeutics (NASDAQ: PRLD) with a Early-Stage Biotech rating.

Goldman Sachs Starts Prelude Therapeutics (PRLD) at Early-Stage Biotech

Fri, 15 May 2026 05:07:25 -0400

Goldman Sachs analyst Corinne Johnson initiates coverage on Prelude Therapeutics (NASDAQ: PRLD) with a Early-Stage Biotech rating.

Prelude Therapeutics (PRLD) PT Raised to $10 at Jefferies

Tue, 12 May 2026 16:02:41 -0400

Jefferies analyst Roger Song raised the price target on Prelude Therapeutics (NASDAQ: PRLD) to $10.00 (from $4.50) while maintaining a Buy rating.

The analyst comments "PRT12396 (JAK2V617F) has entered Ph1 w/ enrollment underway, while FIC KAT6A degrader PRT13722 remains on track for mid ’26 IND w/ Ph1 start in 2H26. Next-gen DAC platform (SMARCA2/4, CDK9) and early mCALR program provide longer-dated upside optionality. B/S materially de-risked post $90M raise, extending runway into 2Q28. Next 12 mos driven by early clinical execution and INCY option value. We increase pipeline and platform from $350M to $500M, PT to $10. Buy."

Prelude Therapeutics (PRLD) PT Raised to $10 at Jefferies

Tue, 12 May 2026 16:02:41 -0400

Jefferies analyst Roger Song raised the price target on Prelude Therapeutics (NASDAQ: PRLD) to $10.00 (from $4.50) while maintaining a Buy rating.

Form 10-Q Prelude Therapeutics For: Mar 31

Tue, 12 May 2026 07:19:00 -0400

si-local-file:///var/storage/secattach/20260512/26472979.html